335 related articles for article (PubMed ID: 17218393)
1. Chronic myeloid leukemia blast crisis arises from progenitors.
Michor F
Stem Cells; 2007 May; 25(5):1114-8. PubMed ID: 17218393
[TBL] [Abstract][Full Text] [Related]
2. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Wodarz D
Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
[TBL] [Abstract][Full Text] [Related]
3. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
4. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Strout MP; Schatz DG
Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
[TBL] [Abstract][Full Text] [Related]
5. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
6. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Avery S; Nadal E; Marin D; Olavarria E; Kaeda J; Vulliamy T; Brito Babapulle F; Goldman JM; Apperley JF
Leuk Res; 2004 May; 28 Suppl 1():S75-7. PubMed ID: 15036946
[TBL] [Abstract][Full Text] [Related]
7. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
8. Imatinib-resistant lymphoid clone of chronic myelogenous leukemia in blast phase arising from B cell-committed progenitor leukemic stem cells.
Kobayashi S; Sato K; Kobayashi A; Osawa Y; Nakamura Y; Kimura F
Ann Hematol; 2011 Mar; 90(3):367-8. PubMed ID: 20556391
[No Abstract] [Full Text] [Related]
9. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
11. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
12. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone].
Kuyama J; Take H
Rinsho Ketsueki; 1995 Dec; 36(12):1353-8. PubMed ID: 8587171
[TBL] [Abstract][Full Text] [Related]
13. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
Bee PC; Gan GG; Teh A; Haris AR
Med J Malaysia; 2006 Dec; 61(5):547-52. PubMed ID: 17623954
[TBL] [Abstract][Full Text] [Related]
15. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
16. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
[TBL] [Abstract][Full Text] [Related]
17. [Molecular pathogenesis of chronic myeloid leukemia].
Sasaki K; Mitani K
Nihon Rinsho; 2009 Oct; 67(10):1894-9. PubMed ID: 19860186
[TBL] [Abstract][Full Text] [Related]
18. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
19. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
[No Abstract] [Full Text] [Related]
20. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]